The clinical significance of Nox2-derived ROS in aging associated microglial dysfunction was further demonstrated using post-mortem midbrain tissues of young (25–38 years old) and elderly (61–85 years old) adults without diagnosed neurodegenerative diseases. The gene discussed is CYBB; the disease is neurodegenerative disease.